Jaguar Health, Inc. is a specialized pharmaceutical company focused on developing plant-based medicines. The biotech company's stock is currently trading at $7.18, a decrease of 8.83% for the day. With a market capitalization of about $478,500, the stock has seen significant volatility, with a 52-week high of $462.00 and a recent low of $7.01.
To address its low share price, Jaguar Health, Inc. enacted a 1-for-35 reverse stock split on April 30, 2026. This corporate action reduces the total number of a company's outstanding shares, which increases the price per share. This action does not change the overall value of the company or an investor's total stake in it.
The strategic split was necessary for Jaguar Health, Inc. to meet Nasdaq's stringent listing requirements. As highlighted by Accesswire, the company was granted an extension until May 15, 2026, to achieve a closing bid price of at least $1.00 for ten straight business days. The reverse split is the biopharmaceutical company's strategy to regain compliance with this rule.
The decision to perform the reverse split received backing from Jaguar Health, Inc. shareholders. During a Special Meeting of Stockholders in April 2026, all five proposals, including the split, were approved, as reported by Accesswire. Following this shareholder approval, Jaguar Health, Inc. common stock began trading on a split-adjusted basis on April 30, 2026.
